keyword
MENU ▼
Read by QxMD icon Read
search

bladder small cell carcinoma

keyword
https://www.readbyqxmd.com/read/28225151/cytopathologic-differential-diagnosis-of-low-grade-urothelial-carcinoma-and-reactive-urothelial-proliferation-in-bladder-washings-a-logistic-regression-analysis
#1
Ebru Cakir, Ulku Kucuk, Emel Ebru Pala, Ozlem Sezer, Rahmi Gokhan Ekin, Ozgur Cakmak
Conventional cytomorphologic assessment is the first step to establish an accurate diagnosis in urinary cytology. In cytologic preparations, the separation of low-grade urothelial carcinoma (LGUC) from reactive urothelial proliferation (RUP) can be exceedingly difficult. The bladder washing cytologies of 32 LGUC and 29 RUP were reviewed. The cytologic slides were examined for the presence or absence of the 28 cytologic features. The cytologic criteria showing statistical significance in LGUC were increased numbers of monotonous single (non-umbrella) cells, three-dimensional cellular papillary clusters without fibrovascular cores, irregular bordered clusters, atypical single cells, irregular nuclear overlap, cytoplasmic homogeneity, increased N/C ratio, pleomorphism, nuclear border irregularity, nuclear eccentricity, elongated nuclei, and hyperchromasia (p ˂ 0...
February 22, 2017: APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica
https://www.readbyqxmd.com/read/28195647/molecular-classification-of-urothelial-carcinoma-global-mrna-classification-versus-tumour-cell-phenotype-classification
#2
Gottfrid Sjödahl, Pontus Eriksson, Fredrik Liedberg, Mattias Höglund
Global mRNA expression analysis is efficient for phenotypic profiling of tumours and has been used to define molecular subtypes for almost every major tumour type. A key limitation is that most tumours are communities of both tumour and non-tumour cells. This problem is particularly pertinent when analysing advanced invasive tumours, known to induce major changes and responses in both the tumour and the surrounding tissue. To identify bladder cancer tumour-cell phenotypes and compare classification by tumour-cell phenotype with classification by global gene expression analysis, we analysed 307 advanced bladder cancers (cystectomised) both by genome gene expression analysis and by immunohistochemistry using antibodies for 28 proteins...
February 13, 2017: Journal of Pathology
https://www.readbyqxmd.com/read/28176958/prognostic-significance-of-microrna-100-in-solid-tumors-an-updated-meta-analysis
#3
Jiangfeng Wang, Miao Yu, Shanghui Guan, Guangyu Zhang, Jianbo Wang, Yufeng Cheng
OBJECTIVE: The aim of this study was to identify prognostic significance of microRNA-100 (miR-100) in solid tumor. METHODS: Literature search was conducted in databases such as PubMed, Embase, and Web of Science, using the following words "(microRNA-100 OR miR-100 OR mir100) AND (tumor OR neoplasm OR cancer OR carcinoma OR malignancy)." The search was updated up until July 10, 2016. Newcastle-Ottawa scale was used to evaluate the quality of studies. Pooled hazard ratio (HR) with 95% confidence interval (CI) for patients' survival was calculated by using a fixed-effects or a random-effects model on the basis of heterogeneity...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28125986/clinical-analysis-of-small-cell-carcinoma-of-the-bladder-in-chinese-nine-case-reports-and-literature-reviews
#4
Zhi Chen, Qingquan Liu, Ruibao Chen, Zhuo Liu, Mingchao Li, Qing Ling, Licheng Wu, Jun Yang, Xiaming Liu, Tao Wang, Zhiquan Hu, Xiaoling Guo, Shaogang Wang, Weiming Yang, Jihong Liu
BACKGROUND: Small cell carcinoma of the bladder (SCCB) is a kind of rare and highly aggressive tumor that is present in an advanced stage and has a propensity for early metastasis. The main presenting symptom of SCCB is hematuria. Surgery, chemotherapy, and radiotherapy, either alone or as a part of combined therapy, have been used as the treatment. The aim of this study is to present our experience with 9 SCCB patients who were treated with different modalities and to share the findings upon reviewing the literatures for patients with SCCB reported in 56 literatures in Chinese...
January 26, 2017: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28115940/rare-occurrence-of-a-poorly-differentiated-neuroendocrine-tumor-of-the-bladder
#5
Katherine Dowd, Charles Rotenberry, Douglas Russell, Mitchell Wachtel, Werner de Riese
Neuroendocrine tumors rarely occur in the urinary bladder. They can be carcinomatous, subdivided into small cell and large cell pathology. Small cell carcinoma of the bladder is a rarity that may present at an advanced pathologic stage. No treatment regimens have been standardized for local or metastatic disease. Review of the recent literature shows equivalent survival data for localized disease treated with chemoradiotherapy combined with either bladder sparing surgery or radical cystectomy. Patients with significant comorbidities are an additional challenge...
2017: Case Reports in Medicine
https://www.readbyqxmd.com/read/28110463/biomarkers-of-renal-tumors-the-current-state-and-clinical-perspectives
#6
REVIEW
Marina O Golovastova, Dmitry O Korolev, Larisa V Tsoy, Vladimir A Varshavsky, Wan-Hai Xu, Andrey Z Vinarov, Evgeni Yu Zernii, Pavel P Philippov, Andrey A Zamyatnin
Renal cell carcinoma (RCC) ranks the first death rate among the urogenital tumors, whereas its incidence follows the incidences of prostate and bladder cancer. The diagnosis of RCC at early stages allows immediately undertaking appropriate treatment, which significantly increases patients' survival rate. Early and accurate diagnosis avoids inadequate treatment, provides the disease progression forecast, and permits to apply more efficient therapy. Unfortunately, the small renal tumors are usually asymptomatic resulting in the late diagnosis and, therefore, low efficacy of treatment...
January 2017: Current Urology Reports
https://www.readbyqxmd.com/read/28104820/immune-checkpoint-inhibitors-in-malignancies-with-mismatch-repair-deficiency-a-review-of-the-state-of-the-current-knowledge
#7
Ali Naboush, Christopher A J Roman, Iuliana Shapira
The use of immune checkpoint inhibitors to treat malignant tumors with microsatellite instability is an emerging new modality. This is based on the observations that these tumors may have a high mutation rate-thus a potential source of tumor-specific neoantigens-and harbor infiltrating cytotoxic T cells in response, suggesting that they may be particularly susceptible to immune checkpoint therapy. PUBMED and ASCO library were systematically reviewed to identify all relevant data that involved the use of immune checkpoint inhibitors in the treatment of cancers with microsatellite instability...
January 19, 2017: Journal of Investigative Medicine: the Official Publication of the American Federation for Clinical Research
https://www.readbyqxmd.com/read/28103658/-etoposide-and-carboplatin-effective-for-treatment-of-small-cell-carcinoma-of-prostate-a-report-of-two-cases
#8
Satoru Yumiba, Toshihisa Asakura, Takayuki Okada, Mototaka Satoh, Mikio Nin, Masao Tsujihata
Case 1 : A 76-year-old man consulted a physician because of pollakisuria, decline of urinary stream. A high level of serum prostate specific antigen (PSA) was detected and he came to our hospital. He was diagnosed to have prostate cancer, cT3aN0M1b, and was treated with combined androgen blockage (CAB). Two years and nine months later, postrenal failure appeared and serum level of neuron-specific enolase (NSE) was 162 ng/ml. We performed re-biopsy of prostate, and pathological examination indicated small cell carcinoma of the prostate...
December 2016: Hinyokika Kiyo. Acta Urologica Japonica
https://www.readbyqxmd.com/read/28101026/transdifferentiation-of-small-cell-carcinoma-of-the-urinary-bladder-from-urothelial-carcinoma-after-transurethral-resection-of-a-bladder-tumor-intravesical-bacillus-calmette-guerin-instillation-and-chemotherapy-a-case-report
#9
Kento Morozumi, Shunichi Namiki, Takashi Kudo, Masataka Aizawa, Naomasa Ioritani, Kazuhiro Sakamoto, Yasuhiro Nakamura
A 73-year-old male underwent transurethral resection of a bladder tumor in August 2010 and April 2011. Pathological examination revealed urothelial carcinoma. After the surgery, chemotherapy and intravesical Bacillus Calmette-Guerin instillation were performed. In September 2014, he once again underwent transurethral resection of the bladder tumor for recurrence, and was again diagnosed with urothelial carcinoma, pT2, by pathological examination. After neoadjuvant chemotherapy, radical cystectomy for tumor recurrence was performed...
September 2016: Case Reports in Oncology
https://www.readbyqxmd.com/read/28056456/bladder-metastases-from-lung-cancer-clinical-and-pathological-implications-a-systematic-review
#10
Francesca Sanguedolce, Domenico Loizzi, Francesco Sollitto, Maurizio Di Bisceglie, Giuseppe Lucarelli, Giuseppe Carrieri, Pantaleo Bufo, Luigi Cormio
Lung cancer is the tumor with the highest incidence in males worldwide and the most common cause of death from cancer overall; its high mortality is mostly due to its propensity to spread to other organs through lymphatic and blood vessels in spite of proper treatment. Bladder metastases from lung cancer are rare, with only 11 cases having been reported, all in recent years. This review aims to discuss some critical points regarding this uncommon condition, namely: (a) lung and bladder tumors share similar etiologic features; (b) almost all bladder metastases from lung cancer arise from lung adenocarcinomas; (c) cytology and superficial bladder biopsy may be falsely negative, since the neoplastic cells coming through the hematogenous route are typically located in the lamina propria and/or muscularis propria of the bladder wall; and (d) the differential diagnosis with primary bladder adenocarcinoma as well as primary and secondary small-cell carcinomas may be challenging...
January 6, 2017: Oncology
https://www.readbyqxmd.com/read/28040422/pure-but-not-mixed-histologic-variants-are-associated-with-poor-survival-at-radical-cystectomy-in-bladder-cancer-patients
#11
Marco Moschini, Shahrokh F Shariat, Roberta Lucianò, David D'Andrea, Beat Foerster, Mohammad Abufaraj, Marco Bandini, Paolo Dell'Oglio, Rocco Damiano, Andrea Salonia, Francesco Montorsi, Alberto Briganti, Renzo Colombo, Andrea Gallina
PURPOSE: To evaluate the impact of pure and mixed histologic variant versus pure urothelial carcinoma in nonmetastatic bladder cancer (BCa) patients treated with radical cystectomy (RC). PATIENTS AND METHODS: We evaluated data from 1067 patients treated with RC and pelvic lymph node dissection between 1990 and 2013 at a single institution tertiary-care referral center. All specimens were evaluated by dedicated uropathologists. Univariable and multivariable Cox regression analyses tested the impact of the presence of pure and mixed histologic variants versus pure urothelial on recurrence, cancer-specific mortality, and overall mortality after accounting for all available confounders...
December 14, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/27991416/small-cell-carcinoma-of-the-bladder-20-year-single-institution-retrospective-review
#12
Kyungsuk Jung, Pooja Ghatalia, Samuel Litwin, Eric M Horwitz, Robert G Uzzo, Richard E Greenberg, Rosalia Viterbo, Daniel M Geynisman, Alexander Kutikov, Elizabeth R Plimack, Marc C Smaldone, Yu-Ning Wong, Marijo Bilusic
INTRODUCTION: Small-cell carcinoma of the bladder is a poorly differentiated neoplasm with aggressive behavior. We analyzed clinical outcomes of patients who were treated at our institution to identify an optimal treatment strategy. MATERIALS AND METHODS: Retrospective chart analysis was performed for patients who were treated for small-cell carcinoma of the bladder at Fox Chase Cancer Center between 1995 and 2015. Survival was compared between different treatment periods (before January 2010 vs...
September 30, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/27979310/argininosuccinate-synthetase-1-loss-in-invasive-bladder-cancer-regulates-survival-through-general-control-nonderepressible-2-kinase-mediated-eukaryotic-initiation-factor-2%C3%AE-activity-and-is-targetable-by%C3%A2-pegylated-arginine-deiminase
#13
Divya Sahu, Sounak Gupta, Andrew M Hau, Kazufumi Nakashima, Mariah Z Leivo, Stephen C Searles, Paul Elson, John S Bomalaski, Darren E Casteel, Gerry R Boss, Donna E Hansel
Loss of argininosuccinate synthetase 1 (ASS1), a key enzyme for arginine synthesis, occurs in many cancers, making cells dependent on extracellular arginine and targetable by the arginine-degrading enzyme pegylated arginine deiminase (ADI-PEG 20). We evaluated ASS1 expression and effects of ASS1 loss in bladder cancer which, despite affecting >70,000 people in the United States annually, has limited therapies. ASS1 loss was identified in conventional and micropapillary urothelial carcinoma, small cell, and squamous cell carcinoma subtypes of invasive bladder cancer, as well as in T24, J82, and UM-UC-3 but not in 5637, RT112, and RT4 cell lines...
December 9, 2016: American Journal of Pathology
https://www.readbyqxmd.com/read/27920687/a-case-of-primary-small-cell-carcinoma-of-the-bladder
#14
Ashita Ono, Yosuke Hirasawa, Mitsumasa Yamashina, Naoto Kaburagi, Takashi Mima, Toru Sugihara, Riu Hamada, Tatsuo Gondo, Makoto Ohori, Toshitaka Nagao, Yoshio Ohno
Primary small-cell carcinoma arising from the bladder (SmCCB) is uncommon. It differs from urothelial carcinoma (UC), the most common type of bladder cancer, with respect to its cell of origin, biology, and prognosis. Biologically, prostatic SmCCB is much more aggressive than UC, and the prognosis for cases with distant metastasis is especially poor. We report here a case of primary SmCCB (cT3bN1M0) treated with radical cystectomy.
September 2016: Case Reports in Oncology
https://www.readbyqxmd.com/read/27878946/targeted-inhibition-of-polo-like-kinase-1-by-a-novel-small-molecule-inhibitor-induces-mitotic-catastrophe-and-apoptosis-in-human-bladder-cancer-cells
#15
Zhe Zhang, Guojun Zhang, Chuize Kong
Bladder cancer is a common cancer with particularly high recurrence after transurethral resection. Despite improvements in neoadjuvant chemotherapy, the outcome of patients with advanced bladder cancer has changed very little. In this study, the anti-tumour activities of a novel Polo-like kinase 1 (PLK1) inhibitor (RO3280) was evaluated in vitro and in vivo in the bladder carcinoma cell lines 5637 and T24. MTT assays, colony-formation assays, flow cytometry, cell morphological analysis and trypan blue exclusion assays were used to examine the proliferation, cell cycle distribution and apoptosis of bladder carcinoma cells with or without RO3280 treatment...
November 23, 2016: Journal of Cellular and Molecular Medicine
https://www.readbyqxmd.com/read/27863432/e-cadherin-downregulation-sensitizes-pten-mutant-tumors-to-pi3k%C3%AE-silencing
#16
África Millán-Uclés, Susana Zuluaga, Miriam Marqués, Jesus Vallejo-Díaz, Lorena Sanz, Ariel E Cariaga-Martínez, Francisco X Real, Ana C Carrera
Alterations in phosphatidylinositol 3-kinase (PI3K) and in PTEN (phosphatase and tensin homolog), the negative regulator of the PI3K pathway, are found in nearly half of human tumors. As PI3Kβ, the main isoform activated in PTEN-mutant tumors, has kinase-dependent and -independent activities, we compared the effects of depleting vs. drug-inhibiting PI3Kβ kinase activity in a collection of diverse tumor types and in a set of bladder carcinoma cell lines grown as xenografts in mice. PI3Kβ depletion (by intratumor injection of PIK3CB siRNA) induced apoptosis and triggered regression of PTEN-mutant tumors more efficiently than PI3Kβ inhibition...
November 16, 2016: Oncotarget
https://www.readbyqxmd.com/read/27846884/future-perspectives-in-melanoma-research-meeting-report-from-the-melanoma-bridge-napoli-december-1st-4th-2015
#17
Paolo A Ascierto, Sanjiv Agarwala, Gerardo Botti, Alessandra Cesano, Gennaro Ciliberto, Michael A Davies, Sandra Demaria, Reinhard Dummer, Alexander M Eggermont, Soldano Ferrone, Yang Xin Fu, Thomas F Gajewski, Claus Garbe, Veronica Huber, Samir Khleif, Michael Krauthammer, Roger S Lo, Giuseppe Masucci, Giuseppe Palmieri, Michael Postow, Igor Puzanov, Ann Silk, Stefani Spranger, David F Stroncek, Ahmad Tarhini, Janis M Taube, Alessandro Testori, Ena Wang, Jennifer A Wargo, Cassian Yee, Hassane Zarour, Laurence Zitvogel, Bernard A Fox, Nicola Mozzillo, Francesco M Marincola, Magdalena Thurin
The sixth "Melanoma Bridge Meeting" took place in Naples, Italy, December 1st-4th, 2015. The four sessions at this meeting were focused on: (1) molecular and immune advances; (2) combination therapies; (3) news in immunotherapy; and 4) tumor microenvironment and biomarkers. Recent advances in tumor biology and immunology has led to the development of new targeted and immunotherapeutic agents that prolong progression-free survival (PFS) and overall survival (OS) of cancer patients. Immunotherapies in particular have emerged as highly successful approaches to treat patients with cancer including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), bladder cancer, and Hodgkin's disease...
November 15, 2016: Journal of Translational Medicine
https://www.readbyqxmd.com/read/27801735/fading-with-time-of-pd-l1-immunoreactivity-in-non-small-cells-lung-cancer-tissues-a-methodological-study
#18
Francesca Giunchi, Alessio Degiovanni, Niccolò Daddi, Rocco Trisolini, Andrea Dell'Amore, Claudio Agostinelli, Andrea Ardizzoni, Michelangelo Fiorentino
Blockade of inhibitory immune checkpoints is currently arising as a potential immunologic option for tumor therapy. Inhibition of programmed cell death protein 1 and/or its specific ligand programmed death-ligand 1 (PD-L1) was effective in clinical trials in advanced melanoma, non-small cell lung cancer (NSCLC) bladder and kidney cancer. The predictive role of the immunohistochemical (IHC) expression of PD-L1 is highly debated. Different reagents, clones, cutoffs of cell expression and subjective interpretation of PD-L1 immunoreactivity in epithelial cells and lymphocytes are the main issue...
October 31, 2016: Applied Immunohistochemistry & Molecular Morphology: AIMM
https://www.readbyqxmd.com/read/27785426/variant-histology-in-bladder-cancer-how-it-should-change-the-management-in-non-muscle-invasive-and-muscle-invasive-disease
#19
REVIEW
Yvonne Klaile, Katrin Schlack, Martin Boegemann, Julie Steinestel, Andres Jan Schrader, Laura-Maria Krabbe
Bladder cancer (BC) is a frequent type of carcinoma with an estimated incidence of approximately 100,000 men and women each year in the European Union (EU) with an associated mortality of 30,000 of these patients. In more than 70% the disease is diagnosed in a non-muscle invasive stage with the chance of minimally invasive, local treatment only, which might be required repetitively due to high rate of recurrence. In contrast, muscle invasive or metastatic stages need multimodal treatment strategies including surgical treatment and chemotherapy (CTX) in neoadjuvant (NAC), adjuvant, or palliative settings...
October 2016: Translational Andrology and Urology
https://www.readbyqxmd.com/read/27777770/safety-and-efficacy-of-anti-pd-1-in-patients-with-baseline-cardiac-renal-or-hepatic-dysfunction
#20
Bridgette A Kanz, Megan H Pollack, Romany Johnpulle, Igor Puzanov, Leora Horn, Alicia Morgans, Jeffrey A Sosman, Suthee Rapisuwon, R Martin Conry, Zeynep Eroglu, Douglas B Johnson
BACKGROUND: Anti-PD-1 therapy is increasingly used in various advanced malignancies. Patients with baseline organ dysfunction are largely excluded from clinical trials. Therefore it is unclear whether anti-PD-1 therapy is safe or effective in this setting. Further, these patients are often not candidates for other anti-cancer therapies, highlighting their need for active treatment options. METHODS: We performed a retrospective analysis of patients from multiple centers with advanced solid tumors and baseline organ dysfunction who received anti-PD-1 therapy...
2016: Journal for Immunotherapy of Cancer
keyword
keyword
68849
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"